Aardvark Therapeutics Establishes Dermatology Subsidiary, Appoints CEO, and Expands Executive Team

summarizeSummary

Aardvark Therapeutics established a new dermatology-focused subsidiary, Ardia Therapeutics, Inc., appointing former COO Bryan Jones as its CEO, while expanding CFO Nelson Sun's role to include COO and hiring Derrick C. Li as Chief Business Officer.

check_boxKey Events

• New Dermatology Subsidiary Established

  Aardvark Therapeutics, Inc. announced the establishment of Ardia Therapeutics, Inc., a new wholly-owned U.S. subsidiary focused on developing a dermatology pipeline, with its lead asset, DIA-615, a potential topical treatment for inflammatory skin diseases like psoriasis.

• COO Transitions to Subsidiary CEO

  Bryan Jones, Ph.D., previously Aardvark's Chief Operating Officer, transitioned to become the Chief Executive Officer of the newly formed Ardia Therapeutics, Inc., effective February 9, 2026.

• CFO Assumes Dual Role as COO

  Nelson Sun, Aardvark's current Chief Financial Officer, has expanded his responsibilities to also serve as the company's Chief Operating Officer, effective February 9, 2026, with no material change to his compensation.

• New Chief Business Officer Appointed

  Derrick C. Li has been appointed as Aardvark Therapeutics' Chief Business Officer, effective February 9, 2026, to lead business development strategy and execution.

auto_awesomeAnalysis

Aardvark Therapeutics is strategically expanding its pipeline by establishing a new wholly-owned subsidiary, Ardia Therapeutics, Inc., dedicated to dermatology. This move diversifies the company's focus beyond its existing metabolic disease programs (ARD-101 for Prader-Willi Syndrome and ARD-201 for obesity) into a new therapeutic area with a 'clinic-ready' lead asset, DIA-615. The appointment of Bryan Jones, formerly Aardvark's COO, as CEO of Ardia, along with the expansion of Nelson Sun's role to CFO and COO, and the addition of Derrick C. Li as Chief Business Officer, signals a significant strengthening and strategic alignment of the executive team to support both the core business and the new dermatology venture. This strategic diversification could unlock new growth avenues and enhance long-term value for shareholders.